United Therapeutics Corporation (UTHR) Stock

About United Therapeutics Corporation

United Therapeutics Corporation is led by CEO Martine A. Rothblatt, employs 1,305 people, headquartered in Silver Spring, US, publicly traded since 1999.

United Therapeutics Corporation (UTHR) stock trades at $587.50 with a market capitalization of $25.20B. The stock is valued at a price-to-earnings (P/E) ratio of 17.74, price-to-book of 3.57, price-to-sales of 7.22. Over the past 52 weeks the stock has ranged between $409.07 and $609.35, and currently trades 3.6% below its 52-week high.

On profitability, United Therapeutics Corporation generates a return on equity (ROE) of 20.18%, above the typical market range of roughly 12-15%, return on capital employed of 21.22%, an operating margin of 45.34%, a net profit margin of 41.56%.

In its most recent fiscal year, United Therapeutics Corporation reported annual revenue of $3.2B, net profit of $1.3B. Over the last 5 fiscal years, revenue grew at an average annual rate of 16.5%, and net profit grew at an average annual rate of 21.0%. Over that span net profit grew faster than revenue, so net margin widened.

The balance sheet shows a debt-to-equity ratio of 0.01 (debt below half of shareholders' equity), a current ratio of 6.60, total assets of $7.9B, $1.6B in cash and equivalents.

UTHR has an average daily trading volume of 651,021 shares, a beta of 0.56 (historically less volatile than the overall market).

United Therapeutics Corporation by the numbers, 2016–2025

Between 2016 and 2025 United Therapeutics Corporation reported revenue of $1.6B rising to $3.2B, a change of +99.1% across 10 years. Compounded, revenue has grown 16.5% a year over five years, 18.0% over three, 10.6% over the last twelve months. Net profit rose to $1.3B.

Operating margin went from 66.4% in 2016 to 47.7% in 2025, a fall of 18.7 percentage points. The most recent net margin is 41.56%. On a trailing twelve-month basis to Jun '26, revenue is $3.2B and net profit $1.3B.

Borrowings stand at $38.0M, cash from operations was $1.6B in the latest year, positive in 9 of the last 10.

Return on equity has averaged 16.2% over five years, and was 18.8% in the most recent year.

The share price itself has compounded at 24.5% a year over five years, 33.6% over three, 94.0% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

United Therapeutics Corporation (UTHR) — frequently asked questions